Clinical Roundup Experimental drug doubles one-year survival in pancreatic cancer trial, Northwestern study finds April 17, 2026Vol.52 No.15
Clinical Roundup First in-human trial primes immune system to accept donor livers, UPMC study finds April 17, 2026Vol.52 No.15
Clinical Roundup DYV800 topical therapy targets tumor acidity, preclinical study finds April 17, 2026Vol.52 No.15
Clinical Roundup E-cigarette taxes reduce vaping; no increase in adult smoking, OSU study finds April 17, 2026Vol.52 No.15
Clinical Roundup Clinical trial aims to address vaginal complaints after breast cancer diagnosis April 17, 2026Vol.52 No.15
Drugs & Targets FDA issues draft guidance on genome editing safety standards April 17, 2026Vol.52 No.15
Conversation with The Cancer Letter Letai: Perceptions aside, money is flowing and the cancer research infrastructure is sturdyNCI expects record-breaking spending on extramural research April 10, 2026Vol.52 No.14By Claire Marie Porter and Paul Goldberg
Guest Editorial America needs a new blueprint for the National Cancer ProgramFirst step: Develop Version 2.0 of Paul Calabresi’s “Cancer at a Crossroads” April 10, 2026Vol.52 No.14By Robert A. Winn
California state-funded institute scraps selection process that put cancer projects at a disadvantageCancer researchers are resubmitting applications to the California Institute for Regenerative Medicine April 10, 2026Vol.52 No.14By Sara Willa Ernst
Cancer Policy President’s budget request would cap indirect costs and fully fund all NIH research projects upfront April 10, 2026Vol.52 No.14By Claire Marie Porter and Jacquelyn Cobb
